- Home
- WTTR vs MLTX Comparison
WTTR vs MLTX Comparison
Compare WTTR & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WTTR | MLTX |
|---|---|---|
| Founded | 2016 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 979.8M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | WTTR | MLTX |
|---|---|---|
| Price | $11.16 | $18.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $15.00 | ★ $30.22 |
| AVG Volume (30 Days) | 753.0K | ★ 2.6M |
| Earning Date | 02-17-2026 | 02-25-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $1,409,889,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $58.10 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.20 | $5.95 |
| 52 Week High | $14.66 | $62.75 |
Technical Indicators
Market Signals| Indicator | WTTR | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.85 | 70.35 |
| Support Level | $10.75 | $11.06 |
| Resistance Level | $11.72 | $14.12 |
| Average True Range (ATR) | 0.36 | 0.96 |
| MACD | 0.04 | 0.29 |
| Stochastic Oscillator | 51.54 | 96.62 |
Price Performance
Historical ComparisonAbout WTTR Select Water Solutions Inc.
Select Water Solutions Inc provides sustainable water and chemical solutions to the energy industry. These solutions are supported by the company's critical water infrastructure assets, chemical manufacturing, and water treatment and recycling capabilities. Its reportable segments are Water Services, Water Infrastructure and Chemical Technologies. It generates the majority of its revenue from Water Services segment.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.